Healthy Volunteers
Conditions
Brief summary
The main aim of Part I of this study is to evaluate the relative bioavailability of a new formulation compared with the approved formulation when a single dose of rhPTH(1-84) is given to healthy volunteers. Bioavailability is the ability of a drug to be absorbed and used by the body. In Part II, the main aim is to assess the dose linearity of the new formulation. Participants will receive 2 doses in Part I and 4 doses in Part II. Participants need to visit their doctor approximately 14 days and 30 days after the last dose of study drug.
Detailed description
This study will be conducted in two parts (Part I and Part II). Part I consists of two treatment periods with 2 sequences and part II consists of four treatment periods with 4 sequences. In Part I, relative bioavailability of Formulation A (Test: 100 microgram \[mcg\] rhPTH\[1-84\]) will be compared with Formulation B (Reference: 100 mcg rhPTH\[1-84\]). In Part II, dose linearity of the new formulation, Formulation A, of rhPTH (1-84) will be assessed based on 4 different dose levels as dose c - f (dose c = 25 mcg, dose d = 50 mcg, dose e = 75 mcg and f = 200 mcg). Both parts may be conducted concurrently.
Interventions
DRUGrhPTH(1-84)
Participants in both part I and part II of the study will receive a single SC injection of rhPTH(1-84) depending upon the treatment sequence allocation on Day 1 of each treatment period.
Sponsors
Takeda Development Center Americas, Inc.
Takeda
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Participants must fulfill all of the following inclusion criteria to be eligible for participation in the study: * Healthy, adult, male or female, 18-65 years of age, inclusive, at screening. Attempts will be made to enroll at least 20% of each sex in each study part. * Continuous non-smoker who has not used nicotine containing products for at least 90 days prior to the first dosing and throughout the study, based on participant self-reporting. * Body mass index (BMI) greater than or equal to (\>=) 18.5 and less than or equal to (\<=) 30.0 kilogram per square meter (kg/m2) at screening. * Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the Investigator or designee including the following: * Serum calcium, parathyroid hormone (PTH), phosphate, and magnesium within laboratory normal limits at screening and check-in. * Vitamin D (1,25(OH)2D3) levels between lower limit of normal and up to 1.5x Upper Limit of Normal (ULN). * Seated blood pressure Beats per minute (bpm) is \>= 89/49 millimeters of mercury (mmHg) and \<=139/89 mmHg at screening. * Seated pulse rate is \>=40 bpm and \<=99 bpm at screening. * QTcF interval is \<=450 millisecond (msec) (males) or \<= 470 msec (females) or ECG findings considered normal or not clinically significant by the Investigator or designee at screening. * Estimated creatinine clearance \>= 80 milliliter per minute (mL/minute) at screening. * Agrees to comply with any applicable contraceptive requirements of the protocol. * Understands the study procedures in the ICF, be able to voluntarily provide written, signed, and dated informed consent, and be willing and able to comply with the protocol.
Exclusion criteria
Participants must not be enrolled in the study if they meet any of the following criteria: * Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study in the opinion of the Investigator or designee. * History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the Investigator or designee. * History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gall bladder removal, or current or recurrent disease that could affect the action, absorption, or disposition of the study drug, or clinical or laboratory assessments. * Participants who are at increased baseline risk for osteosarcoma such as participants with Paget's disease of bone or unexplained elevations of alkaline phosphatase (ALP), hereditary disorders predisposing to osteosarcoma or a prior history of external beam or implant radiation therapy involving the skeleton. * History of any illness that, in the opinion of the Investigator or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study. * History or presence of alcoholism or drug abuse, in the opinion of the Investigator or designee, within the past 2 years prior to the first dosing. * Male participants who consume more than 21 units of alcohol per week or 3 units per day. Female participants who consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit=1 beer or 1 wine (5 ounces (oz)/150 in milliliters (mL) or 1 liquor (1.5 oz/40 mL) or 0.75 oz alcohol). * Positive urine drug or alcohol results at screening or check-in. * History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds. * History of abnormalities of calcium homeostasis including hyperparathyroidism, hypoparathyroidism, hyperthyroidism, Cushing's syndrome, hypercalcemia, hypocalcemia, osteoporosis, or any other calcium disorder. * Female participants who have a positive pregnancy test or who are lactating. * Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV). * Has tattoo(s) or scarring at or near the site of injection or any other condition which may interfere with injection site examination, in the opinion of the Investigator or designee. * Routine consumption of more than 2 units of caffeine per day or participants who experience caffeine withdrawal headaches. A unit of caffeine is contained in the following items: one 6 oz (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one 12 oz cup of tea, three 1 oz (85 g) chocolate bars. * Prior screen failure, randomization, participation, or enrollment in this study or prior exposure to any exogenous PTH, PTH fragments or analogs 3 months prior to dosing with rhPTH(1-84). * Unable to refrain from or anticipates the use of any medication or substance (including prescription or over-the-counter, vitamin supplements, natural or herbal supplements) Medication, Supplements, and Dietary Products) for the prohibited time period. * Has been on a diet incompatible with the study diet or had any substantial changes in eating habits, in the opinion of the Investigator or designee, within the 30 days prior to the first dosing and throughout the study. * Donation of blood or significant blood loss within 60 days prior to the first dosing. * Plasma donation within 7 days prior to the first dosing. * Participation in another clinical study within 30 days or 5 half-lives of the study drug prior to the first dosing. The 30-day window or 5 half-lives will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Treatment Period 1 of the current study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs Values | From start of study drug administration up to Day 34 | Vital sign assessments included systolic and diastolic blood pressure, pulse rate and body temperature. Any change in vital signs which are deemed clinically significant by the investigator were reported. |
| Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose | AUCinf was the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC was be used as a measure of drug exposure. It was derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. |
| Part I: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose | Cmax referred to the maximum (or peak) concentration that a drug achieved in the body after the drug had been administrated. |
| Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose | Cmax referred to the maximum (or peak) concentration that a drug achieved in the body after the drug had been administrated. |
| Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose | AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration. |
| Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose | AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration. |
| Part I: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose | AUCinf was the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC was be used as a measure of drug exposure. It was derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs | From start of study drug administration up to Day 34 | Any change in ECG assessments which were deemed clinically significant by the investigator were reported. |
| Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | From start of study drug administration up to Day 34 | Clinical laboratory tests included hematology, chemistry, and urinalysis. Any changes in clinical laboratory results which are deemed clinically significant by the investigator were reported. |
| Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From start of study drug administration up to Day 34 | An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was an adverse event with a start date on or after the first dose of Investigational product (IP), or a start date before the date of the first dose of IP but increased in severity on or after the date of the first dose of IP. Number of participants with TEAEs was reported. |
Countries
United States
Participant flow
Recruitment details
This study was conducted at single site in the United States of America from 29 November 2021 (first participant first visit) and 15 April 2022 (last participant last visit).
Pre-assignment details
Study was conducted in 2 parts: Part 1 (To Assess Relative Bioavailability) and Part 2 (Dose Linearity). A total of 96 participants (84 participants in Part I and 12 participants in Part II) were enrolled in this study.
Participants by arm
| Arm | Count |
|---|---|
| Part I: Sequence AB Participants received a single SC injection of 100 mcg rhPTH(1-84) (Treatment A) on Day 1 of treatment period 1 followed by 100 mcg rhPTH (1-84) (Treatment B) on Day 1 of treatment period 2. A washout period of 96 hours was maintained between treatment periods 1 and 2. | 42 |
| Part I: Sequence BA Participants received a single SC injection of 100 mcg rhPTH(1-84) (Treatment B) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Treatment A) on Day 1 of treatment period 2. A washout period of 96 hours was maintained between treatment periods 1 and 2. | 42 |
| Part II: Sequence CDEF Participants received a single SC injection of 25 mcg (Treatment C) rhPTH(1-84) on Day 1 of treatment period 1 followed by 50 mcg (Treatment D) rhPTH(1-84) on Day 1 of treatment period 2 followed by 75 mcg (Treatment E) rhPTH(1-84) on Day 1 of treatment period 3 followed by 200 mcg (Treatment F) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours was maintained between each treatment periods 1, 2, 3 and 4. | 3 |
| Part II: Sequence DFCE Participants received a single SC injection of 50 mcg (Treatment D) rhPTH(1-84) on Day 1 of treatment period 1 followed by 200 mcg (Treatment F) rhPTH(1-84) on Day 1 of treatment period 2 followed by 25 mcg (Treatment C) rhPTH(1-84) on Day 1 of treatment period 3 followed by 75 mcg (Treatment E) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours was maintained between each treatment periods 1, 2, 3 and 4. | 3 |
| Part II: Sequence ECFD Participants received a single SC injection of 75 mcg rhPTH(1-84) (Treatment E) on Day 1 of treatment period 1 followed by 25 mcg rhPTH(1-84) (Treatment C) on Day 1 of treatment period 2 followed by 200 mcg rhPTH(1-84) (Treatment F) on Day 1 of treatment period 3 followed by 50 mcg rhPTH(1-84) (Treatment D) on Day 1 of treatment period 4. A washout period of 48 hours was maintained between each treatment periods 1, 2, 3 and 4. | 3 |
| Part II: Sequence FEDC Participants received a single SC injection of 200 mcg (Treatment F) rhPTH(1-84) on Day 1 of treatment period 1 followed by 75 mcg (Treatment E) rhPTH(1-84) on Day 1 of treatment period 2 followed by 50 mcg (Treatment D) rhPTH(1-84) on Day 1 of treatment period 3 followed by 25 mcg (Treatment C) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours was maintained between each treatment periods 1, 2, 3 and 4. | 3 |
| Total | 96 |
Baseline characteristics
| Characteristic | Part I: Sequence AB | Part I: Sequence BA | Part II: Sequence CDEF | Part II: Sequence DFCE | Part II: Sequence ECFD | Part II: Sequence FEDC | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 41.5 years STANDARD_DEVIATION 10.37 | 45.3 years STANDARD_DEVIATION 12.24 | 36.7 years STANDARD_DEVIATION 8.14 | 38.0 years STANDARD_DEVIATION 4.36 | 45.7 years STANDARD_DEVIATION 5.51 | 40.0 years STANDARD_DEVIATION 6.24 | 43.0 years STANDARD_DEVIATION 10.97 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 35 Participants | 30 Participants | 3 Participants | 2 Participants | 2 Participants | 2 Participants | 74 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 12 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 22 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 5 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 37 Participants | 36 Participants | 3 Participants | 3 Participants | 3 Participants | 1 Participants | 83 Participants |
| Sex: Female, Male Female | 27 Participants | 24 Participants | 1 Participants | 1 Participants | 2 Participants | 1 Participants | 56 Participants |
| Sex: Female, Male Male | 15 Participants | 18 Participants | 2 Participants | 2 Participants | 1 Participants | 2 Participants | 40 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 84 | 0 / 84 | 0 / 12 | 0 / 12 | 0 / 12 | 0 / 12 |
| other Total, other adverse events | 10 / 84 | 9 / 84 | 2 / 12 | 4 / 12 | 3 / 12 | 2 / 12 |
| serious Total, serious adverse events | 0 / 84 | 0 / 84 | 0 / 12 | 0 / 12 | 0 / 12 | 0 / 12 |
Outcome results
Primary
Number of Participants With Clinically Significant Changes in Vital Signs Values
Vital sign assessments included systolic and diastolic blood pressure, pulse rate and body temperature. Any change in vital signs which are deemed clinically significant by the investigator were reported.
Time frame: From start of study drug administration up to Day 34
Population: Safety set included all participants who received at least one dose of the study drug. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I: Treatment A | Number of Participants With Clinically Significant Changes in Vital Signs Values | 1 Participants |
| Part I: Treatment B | Number of Participants With Clinically Significant Changes in Vital Signs Values | 0 Participants |
| Part II: Treatment E | Number of Participants With Clinically Significant Changes in Vital Signs Values | 0 Participants |
| Part II: Treatment F | Number of Participants With Clinically Significant Changes in Vital Signs Values | 0 Participants |
| Part II: Treatment E | Number of Participants With Clinically Significant Changes in Vital Signs Values | 0 Participants |
| Part II: Treatment F | Number of Participants With Clinically Significant Changes in Vital Signs Values | 0 Participants |
Primary
Part I: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84)
AUCinf was the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC was be used as a measure of drug exposure. It was derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Time frame: Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose
Population: PK Set included all participants who had at least one measurable predose (baseline) and one postdose concentration of parathyroid hormone (PTH). Here, 'Overall number of participants analyzed' signifies participants who were evaluable for this outcome measure. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part I: Treatment A | Part I: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | 559.7 pg*hr/ml | Geometric Coefficient of Variation 53.2 |
| Part I: Treatment B | Part I: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | 663.7 pg*hr/ml | Geometric Coefficient of Variation 44 |
90% CI: [0.7576, 0.9375]
Primary
Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84)
AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration.
Time frame: Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose
Population: Pharmacokinetic (PK) Set included all participants who had at least one measurable predose (baseline) and one postdose concentration of parathyroid hormone (PTH). Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part I: Treatment A | Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | 471.9 picogram*hour/milliliter (pg*hr/ml) | Geometric Coefficient of Variation 57.4 |
| Part I: Treatment B | Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | 603.1 picogram*hour/milliliter (pg*hr/ml) | Geometric Coefficient of Variation 50.3 |
90% CI: [0.7109, 0.8611]
Primary
Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84)
AUCinf was the area under the curve extrapolated to infinity, calculated using the observed value of the last non-zero concentration. AUC was be used as a measure of drug exposure. It was derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.
Time frame: Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose
Population: PK Set included all participants who had at least one measurable predose (baseline) and one postdose concentration of parathyroid hormone (PTH). Here, 'Overall number of participants analyzed' signifies participants who were evaluable for this outcome measure. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part I: Treatment A | Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | 83.91 pg*hr/ml | Geometric Coefficient of Variation 19.5 |
| Part I: Treatment B | Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | 217.0 pg*hr/ml | Geometric Coefficient of Variation 33.2 |
| Part II: Treatment E | Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | 364.7 pg*hr/ml | Geometric Coefficient of Variation 39 |
| Part II: Treatment F | Part II: Area Under the Plasma Concentration- Time Curve From Time Zero to Infinity (AUCinf) of rhPTH(1-84) | 1117 pg*hr/ml | Geometric Coefficient of Variation 59.6 |
Comparison: A linear regression model using was used, including sequence and period as fixed effects, subject within sequence as a random effect, and ln(dose) as a covariate.95% CI: [1.0431, 1.5215]
Primary
Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84)
AUClast was a measure of the total amount of drug in the plasma from time zero to time of the last measurable concentration.
Time frame: Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose
Population: Pharmacokinetic (PK) Set included all participants who had at least one measurable predose (baseline) and one postdose concentration of parathyroid hormone (PTH). Here, 'Overall number of participants analyzed' signifies participants who were evaluable for this outcome measure. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part I: Treatment A | Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | 44.34 pg*hr/ml | Geometric Coefficient of Variation 161.7 |
| Part I: Treatment B | Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | 97.74 pg*hr/ml | Geometric Coefficient of Variation 123.4 |
| Part II: Treatment E | Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | 259.2 pg*hr/ml | Geometric Coefficient of Variation 57.5 |
| Part II: Treatment F | Part II: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) | 1009 pg*hr/ml | Geometric Coefficient of Variation 61.3 |
Comparison: A linear regression model was used, including sequence and period as fixed effects, subject within sequence as a random effect, and ln(dose) as a covariate.95% CI: [1.2929, 1.7862]
Primary
Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84)
Cmax referred to the maximum (or peak) concentration that a drug achieved in the body after the drug had been administrated.
Time frame: Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose
Population: PK Set included all participants who had at least one measurable predose (baseline) and one postdose concentration of parathyroid hormone (PTH). Here, 'Overall number of participants analyzed' signifies participants who were evaluable for this outcome measure. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part I: Treatment A | Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | 28.05 pg/ml | Geometric Coefficient of Variation 50.4 |
| Part I: Treatment B | Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | 43.06 pg/ml | Geometric Coefficient of Variation 47.5 |
| Part II: Treatment E | Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | 77.46 pg/ml | Geometric Coefficient of Variation 55.8 |
| Part II: Treatment F | Part II: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | 250.2 pg/ml | Geometric Coefficient of Variation 41.5 |
Comparison: A linear regression model was used, including sequence and period as fixed effects, subject within sequence as a random effect, and ln(dose) as a covariate.95% CI: [0.938, 1.2493]
Primary
Part I: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84)
Cmax referred to the maximum (or peak) concentration that a drug achieved in the body after the drug had been administrated.
Time frame: Pre-dose, 0.08, 0.16, 0.33, 0.5, 0.75, 1.0, 1.25,1.5,2.0, 2.5, 3, 4, 6, 8, 12, 16, and 24 hours post dose
Population: PK Set included all participants who had at least one measurable predose (baseline) and one postdose concentration of parathyroid hormone (PTH). Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part I: Treatment A | Part I: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | 150.8 picogram per milliliter (pg/ml) | Geometric Coefficient of Variation 53.2 |
| Part I: Treatment B | Part I: Maximum Observed Plasma Concentration (Cmax) of rhPTH(1-84) | 185.1 picogram per milliliter (pg/ml) | Geometric Coefficient of Variation 52.7 |
90% CI: [0.7462, 0.8893]
Secondary
Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values
Clinical laboratory tests included hematology, chemistry, and urinalysis. Any changes in clinical laboratory results which are deemed clinically significant by the investigator were reported.
Time frame: From start of study drug administration up to Day 34
Population: Safety set included all participants who received at least one dose of the study drug. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I: Treatment A | Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | 0 Participants |
| Part I: Treatment B | Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | 0 Participants |
| Part II: Treatment E | Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | 1 Participants |
| Part II: Treatment F | Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | 1 Participants |
| Part II: Treatment E | Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | 0 Participants |
| Part II: Treatment F | Part I and II: Number of Participants With Clinically Significant Changes in Clinical Laboratory Values | 0 Participants |
Secondary
Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs
Any change in ECG assessments which were deemed clinically significant by the investigator were reported.
Time frame: From start of study drug administration up to Day 34
Population: Safety set included all participants who received at least one dose of the study drug. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I: Treatment A | Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs | 0 Participants |
| Part I: Treatment B | Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs | 0 Participants |
| Part II: Treatment E | Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs | 0 Participants |
| Part II: Treatment F | Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs | 0 Participants |
| Part II: Treatment E | Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs | 0 Participants |
| Part II: Treatment F | Part I and II: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters Reported as TEAEs | 0 Participants |
Secondary
Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A TEAE was an adverse event with a start date on or after the first dose of Investigational product (IP), or a start date before the date of the first dose of IP but increased in severity on or after the date of the first dose of IP. Number of participants with TEAEs was reported.
Time frame: From start of study drug administration up to Day 34
Population: Safety set included all participants who received at least one dose of the study drug. Data was collected and analyzed as per individual treatment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part I: Treatment A | Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 19 Participants |
| Part I: Treatment B | Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 15 Participants |
| Part II: Treatment E | Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 2 Participants |
| Part II: Treatment F | Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 4 Participants |
| Part II: Treatment E | Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 3 Participants |
| Part II: Treatment F | Part I and II: Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 2 Participants |